Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $195.92.

A number of research analysts have commented on ASND shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday, September 16th. Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $190.00 price objective (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC boosted its position in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the period. Profund Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 85 shares in the last quarter. Rhumbline Advisers lifted its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the 1st quarter valued at about $36,000. Finally, Bessemer Group Inc. increased its stake in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares during the period.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $130.32 on Friday. The company has a market capitalization of $7.59 billion, a price-to-earnings ratio of -13.56 and a beta of 0.64. Ascendis Pharma A/S has a 12 month low of $85.70 and a 12 month high of $161.00. The company’s fifty day moving average price is $134.73 and its two-hundred day moving average price is $134.52.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -7.2 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.